Forsberg, P., Andorsky, D., Rifkin, R. M., Yasenchak, C. A., Narang, M., Melear, J. M., Schade, H. H., Gandhi, M., Simmons, G., Baljevic, M., Yimer, H. A., Patel, K., Gillespie-Twardy, A. L., Manda, S., Renshaw, J. S., Fowler, J., Lin, T. S., Blanc, T. L., Xu, W. (2026). Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7510